Nanocarrier-based immunotherapy in cancer management and research. - Wikidata - wikimedia - TriplyDB

Nanocarrier-based immunotherapy in cancer management and research.

Nanocarrier-based immunotherapy in cancer management and research.

http://www.wikidata.org/entity/Q37031671

about

The janus facet of nanomaterials

P2860

Q28083583-A3EF4DB2-4410-4814-8999-D779BE687403

P2860

Nanocarrier-based immunotherapy in cancer management and research.

http://www.wikidata.org/entity/Q37031671

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 June 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Nanocarrier-based immunotherapy in cancer management and research.

@en

Nanocarrier-based immunotherapy in cancer management and research.

@nl

type

label

Nanocarrier-based immunotherapy in cancer management and research.

@en

Nanocarrier-based immunotherapy in cancer management and research.

@nl

prefLabel

Nanocarrier-based immunotherapy in cancer management and research.

@en

Nanocarrier-based immunotherapy in cancer management and research.

@nl

P1433

Q37031671-1BA15A2F-5403-4EEB-B32D-E85D6EC4D5DC

P1476

Q37031671-D8D7B6A8-141F-437A-9FB6-302EF525F216

P2093

Q37031671-2D8108CB-F223-4BCB-AF22-1CB36DDCACF2

Q37031671-684BB75D-2939-4B70-86CF-B0C60E070D98

P2860

Q37031671-013BB52F-4FFC-4040-A9E1-ECEFE94C6BA7

Q37031671-061D4879-A6D5-417B-93F2-21D3ECE1560A

Q37031671-0B34E463-4B1C-4145-ABAC-FAEEA55AE5CA

Q37031671-0B9D8770-E52B-4FDF-9D47-B8AB1A6F4A5A

Q37031671-0F14AEC2-2F0F-4749-81AB-B5201BE8ABE1

Q37031671-106808BA-7DEB-4ACF-901F-CE3AC9B524CA

Q37031671-1331AE3A-AA79-4C5F-A85B-C1D69E708B78

Q37031671-14720332-9F07-4DBB-A2E0-62B7C5745E3E

Q37031671-158A5FDF-03D0-47DE-B2A5-467F669085BB

Q37031671-16DB7702-AB7A-4C22-BAE7-CF8D8D0463A7

P304

Q37031671-E0294F6D-896F-440C-A7B8-4B3FA24A2F06

P31

Q37031671-CAD94851-DE57-4A06-8D1D-1E90D61677B4

P356

Q37031671-95EAD904-58F5-4175-BBA1-A0CFD8C1C868

P478

Q37031671-CA0A7B46-D25D-470A-8CD3-D3E427523760

P577

Q37031671-82047067-FCD1-49C0-A84E-8C32C08703AC

P5875

Q37031671-4A48729A-B78D-42D9-83D9-989802950F0F

P698

Q37031671-5DEB5AFB-A98C-4FF5-B49D-FB1C55D45878

P921

Q37031671-34783AE3-730B-4ED2-80F0-E3111DC47D18

Q37031671-8E0B3B37-77F7-4E7F-9BAC-8D59027CBDBF

P932

Q37031671-820A7BE3-34AA-4AB3-B7B2-2C6AA489ABBF

P356

P1433

ImmunoTargets and therapy

P1476

Nanocarrier-based immunotherapy in cancer management and research.

@en

P2093

Manu Smriti Singh

http://www.w3.org/2001/XMLSchema#string

Sangeeta Bhaskar

http://www.w3.org/2001/XMLSchema#string

P2860

Particle-mediated delivery of cytokines for immunotherapy

Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy

The three Es of cancer immunoediting

Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism

Cancer immunotherapy via dendritic cells

Immunological properties of engineered nanomaterials

Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.

Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.

In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells.

Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice.

P304

121-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/ITT.S62471

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263464777

http://www.w3.org/2001/XMLSchema#string

P698

27471704

http://www.w3.org/2001/XMLSchema#string

P921

P932

4918240

http://www.w3.org/2001/XMLSchema#string